Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow DiaMedica Therapeutics Inc.

Get SEC filing alerts via email and in your feed for DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, to treat severe ischemic diseases like acute ischemic stroke and preeclampsia. Its therapies aim to improve blood flow, reduce inflammation, and promote vascular health. The company focuses on clinical trials, regulatory approval, and strategic partnerships to address unmet medical needs in neurology and obstetrics markets worldwide.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from DiaMedica Therapeutics Inc.

1
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $10M Net Loss and Decrease in Total Assets for Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $32.8 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $8.6 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $7.7 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $7.7 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports $24.4 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
DiaMedica Therapeutics Inc. DiaMedica Therapeutics Reports Decreased Assets, Increased R&D Expenses, and Operating Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments